Drug Trial Radar · NCT06198556
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Jan 14, 2024
Primary completion
Feb 5, 2024
Study completion Feb 5, 2024
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy adult subjects after oral administration of HRS-1167 tablets. The secondary objective of the study is to evaluate the safety of HRS-1167 alone and when co-administered with rifampicin.
Conditions
- Advanced Solid Tumor
Interventions
HRS-1167 tablets; rifampicinDrug
HRS-1167 tablets single oral dose of HRS-1167 or co-administered with rifampicin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics parameters of HRS1167: CmaxTime frame: Based on pre-dose, 0-72 hours post-dose sampling times
- Pharmacokinetics parameters of HRS1167: AUC0-tTime frame: Based on pre-dose, 0-72 hours post-dose sampling times
- Pharmacokinetics parameters of HRS1167: AUC0-infTime frame: Based on pre-dose, 0-72 hours post-dose sampling times
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.